Eisai Co., Ltd. (ESAIY)

Market Cap	10.44B
Revenue (ttm)	4.56B
Net Income (ttm)	202.95M
Shares Out	n/a
EPS (ttm)	0.71
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,002
Open	9.23
Previous Close	9.37
Day's Range	9.23 - 9.37
52-Week Range	8.42 - 14.43
Beta	-0.08
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2024

About Eisai

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1941
• Employees: 11,067
• Stock Exchange: OTCMKTS
• Ticker Symbol: ESAIY

Financial Performance

In 2023, Eisai's revenue was 741.75 billion, a decrease of -0.36% compared to the previous year's 744.40 billion. Earnings were 42.41 billion, a decrease of -23.50%.

Financial numbers in JPY